IL1B and myeloid sarcoma: Recent data suggest that anti‐TNFα therapy has a potential role on the induction of demyelination of the CNS, while IL‐1β can actually promote remyelination.[56, 57] These studies indicate an insufficient role of preserving BBB integrity in later stage or in chronic plaques to alleviate progressive MS.